SCHEMBL712666

SCHEMBL712666

Cn1nc(CC(C)(C)C)cc1Nc1ccc(S(=O)(=O)Nc2nccs2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.49
MEN1 O00255 3/20 0.49
ALDH1A1 P00352 4/20 0.49
LMNA P02545 3/20 0.49
TDP1 Q9NUW8 2/20 0.49
KDM4E B2RXH2 1/20 0.49
CYP2C9 P11712 1/20 0.49
EDNRA P25101 1/20 0.49
SLC6A4 P31645 1/20 0.49
ADRA1A P35348 1/20 0.49
PRMT6 Q96LA8 1/20 0.49
PKM P14618 4/20 0.48
SMN1; SMN2 Q16637 2/20 0.46
EGFR P00533 2/20 0.46
KDR P35968 2/20 0.46
SCN1A P35498 1/20 0.46
SCN1B Q07699 1/20 0.46
SCN5A Q14524 1/20 0.46
SCN8A Q9UQD0 1/20 0.46
PPIA P62937 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL710002 0.87 SCN9A (0.47) SCN1ASCN1BSCN5ASCN8A
SCHEMBL714602 0.86 KMT2A (0.53) KMT2AMEN1ALDH1A1LMNATDP1
SCHEMBL712892 0.83 SCN9A (0.63) KMT2AMEN1LMNAKDM4EPKM
SCHEMBL711670 0.83 SCN3A (0.58) KMT2AMEN1ALDH1A1PKMSCN5A
SCHEMBL713215 0.82 ALDH1A1 (0.54) KMT2AMEN1ALDH1A1LMNATDP1
SCHEMBL712645 0.82 PKM (0.61) KMT2AMEN1ALDH1A1TDP1KDM4E
SCHEMBL711091 0.81 SCN9A (0.53) KMT2AMEN1LMNAPKMSMN1; SMN2
SCHEMBL713598 0.81 SCN9A (0.51) KMT2AMEN1LMNAPKMSMN1; SMN2
SCHEMBL711825 0.80 ALDH1A1 (0.55) KMT2AMEN1ALDH1A1LMNATDP1
SCHEMBL711876 0.80 SCN9A (0.57) LMNASMN1; SMN2SCN1ASCN5ASCN8A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US claimed
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US disclosed
EP-2173743-A2 SODIUM CHANNEL INHIBITORS Icagen, Inc. (US) 2010-04-14 EP disclosed
US-20090023740-A1 SODIUM CHANNEL INHIBITORS ICAGEN (US) 2009-01-22 US disclosed
WO-2009012242-A2 SODIUM CHANNEL INHIBITORS ICAGEN, INC. (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023740-A1 SODIUM CHANNEL INHIBITORS TRPV1, SCN1A, SCN2A KMT2A 1945/4885MEN1 4426/4885ALDH1A1 3333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.